Evaluation of the efficacy and safety of NRL/2019/JC capsules in knee osteoarthritis: A randomized, double-blind, placebo controlled crossover clinical study. - NI

etsurf Communications Pvt Ltd0 个研究点目标入组 108 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Male and/or female volunteers aged between 40 to 60 years both inclusive.
•BMI greater than or equal to 24 Kg/m2 and less than or equal to 38 Kg/m2
•Willing to come for regular follow-up visits.
•Patients diagnosed with osteoarthritis of the knee based on the American College of Rheumatology (ACR) criteria.

•Patients with congenital arthropathy, rheumatoid arthritis, active gout, other type of arthritis with/without inflammation e.g. septic , fibromyalgia or collagen vascular disease
•Patients with known history of coagulopathies
•Osteoarthritis of any other joint except knee
•Patients with history of major trauma or surgery in the knee joint
•Patients with uncontrolled diabetes and hypertension
•Body mass index (BMI) >38 kg/m2.
•Patients with any severe cardiac, renal and hepatic disease
•Pregnant and lactating women
•Patients who participated in any clinical trial within 30 days before enrollment into the study
•Any other condition which the Principal Investigator thinks may jeopardize the study

发起方

etsurf Communications Pvt Ltd